News for Aligos Therapeutics, Inc. (ALGS)

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS, ”œAligos”), a clinical stage biotechnology company focuse

**media[561850]**

Aligos Therapeutics (ALGS) reports Q4 loss of $13.08 per share, missing estimates.

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS), a clinical stage biotechnology company focused on improving

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a significant transaction involving Aligos Therapeutics Inc (ALGS). The firm reduced i

**media[538636]**

Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN

One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers.

Aligos Therapeutics stock soars to 52-week high of $42.99

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS, ”œAligos”, ”œCompany”), a clinical stage biopharmaceuti

Aligos Therapeutics focuses on ALG-000184 for CHB and ALG-055009 for MASH, targeting large, underserved markets with growing TAMs. Read more here.

Aligos Therapeutics to Present at Investor Conferences in December

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS) a clinical stage biopharmaceutical company focused on improvi

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. ( ALGS, ”œAligos”), a clinical stage biopharmaceutical company foc

**media[470814]**

United Therapeutics (UTHR), a biotechnology firm focused on developing treatments for pulmonary arterial hypertension, saw its stock price fall by 2.45%. The st

Aileron Therapeutics, Inc. (ALRN) recently experienced a significant stock drop of 5.26%, bringing its price to $3.60 per share. The trading volume reached 40,4